close
MENU
How to guide
How to guide
Home
NBR Marketplace
The NBR List
NBR Video

Categories

General Business Investment Economics Te Ao Māori Politics Infrastructure Australia Tech & Innovation Finance Law Professional Services Primary Industries Retail Property Deals Marketing & Media Tourism Energy Luxury Property Aviation News Comings & Goings

Analysis

All Economy Matters Edwards on Politics Hunter’s Corner Last Word Margin Call On the Money Shoeshine Underarm NBR Focus

Featured

The NBR Podcast Morning Brew The Grind Entrepreneurs Your Business Beehive Banter Toil & Trouble Market Outlook Dollars & Sense Local Edge Private Bin Audio Articles Podcasts NZ Aviation News Back Issues NBR Radar (Archive) Opinion (Archive) NBR Rich List (Archive)
Investment
3 mins to read
1

Pacific Edge seeks to raise $20m after losing US test coverage

The raise will extend its cash runway while it seeks Medicare coverage and reimbursement.

Pacific Edge produces the Cxbladder test.

Fiona Rotherham Fri, 30 May 2025

Cancer diagnostics company Pacific Edge has announced a long-expected capital raise after it lost US Medicare funding for its bladder cancer tests.

The NZX-listed company hopes to raise $20 million through a placement of $15m new shares to selected investors and an offer of $5m new shares to retail

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
View terms and conditions.
Individual
Group membership
NBR Marketplace

Smartphone Only Subscription

NZ$29.95 / monthly

Monthly Premium Online Subscription

NZ$49.95 / monthly

Smartphone Only Annual Subscription

NZ$299.00 / yearly

Yearly Premium Online Subscription

NZ$499.00 / yearly

Premium Group Membership 10 Users

NZ$385+GST / monthly

$38.5 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$660+GST / monthly

$33 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1375+GST / monthly

$27.5 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$2100+GST / monthly

$21 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$999.00 / yearly

Already have an account? Login
Fiona Rotherham Fri, 30 May 2025
Contact the Writer: fiona@nbr.co.nz
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Tags
Pacific Edge Medicare Peter Meintjes Chris Gallaher capital raise
Company profile
Powered by: nzx logo
Change:
Price
Previous Close
Turnover
Movement
Volume
Avg Daily Volume
Daily High
Daily Low
52 Week High
52 Week Low

Free News Alerts

Sign up to get the latest stories and insights delivered to your inbox – free, every day.

I’m already subscribed/joined
Related News
Investment
2

Investors cheered by Pacific Edge news
Investment
2

Pacific Edge now in a ‘challenging spot,’ analyst says
Investment
2

US court declines to intervene in Pacific Edge funding crisis
Tech & Innovation
1

Pacific Edge’s share price leaps on new US reimbursement hope
Investment

Pacific Edge may take legal action over cancer test blow

Free News Alerts

Sign up to get the latest stories and insights delivered to your inbox – free, every day.

I’m already subscribed/joined
Company profile
Powered by: nzx logo
Change:
Price
Previous Close
Turnover
Movement
Volume
Avg Daily Volume
Daily High
Daily Low
52 Week High
52 Week Low
Related News
Investment
2

Investors cheered by Pacific Edge news
Investment
2

Pacific Edge now in a ‘challenging spot,’ analyst says
Investment
2

US court declines to intervene in Pacific Edge funding crisis
Tech & Innovation
1

Pacific Edge’s share price leaps on new US reimbursement hope
Investment

Pacific Edge may take legal action over cancer test blow
Pacific Edge seeks to raise $20m after losing US test coverage
Investment,
109409
true
Subscribe Login